Tipranavir (Aptivus) for HIV

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1219, 2005, Pages 83-84

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; ENFUVIRTIDE; ERGOT ALKALOID; FLECAINIDE; FLECAINIDE ACETATE; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; MIDAZOLAM; NELFINAVIR; PIMOZIDE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TIPRANAVIR; TRIAZOLAM; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; SHORT SURVEY; VOMITING; ADULT; ARTICLE; DRUG EFFECT; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIDINES; PYRONES; VIRUS REPLICATION;

EID: 27244445346     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (7)

1. BA Larder et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14:1943.
2. NK Back et al. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 2000; 14:101.
3. S Rusconi et al. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44:1328.
4. S McCallister et al. Twenty-four week combined analysis of the tipranavir (TPV) RESIST studies of 1483 treatment-experienced patients given either tipranavir/ritonavir (TPV/r) or an optimized standard of care regimen using one of four ritonavir-boosted comparator PIs (CPI/r). HIV DART, Montego Bay, Jamaica, December 12-16, 2004. Abstract 60.
5. D Cooper et al. 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR). 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 22-25, 2005. Available at www.retroconference.org. Paper no. 560.
6. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.
7. Drug interactions. Med Lett Drugs Ther 2003; 45:46.